Treatment algorithms for high responders: What we can learn from randomized controlled trials, real-world data and models

Panagiotis Drakopoulos, Yakoub Khalaf, Sandro C Esteves, Nikolaos P Polyzos, Sesh K Sunkara, Daniel Shapiro, Botros Rizk, Hong Ye, Michael Costello, Yulia Koloda, Bruno Salle, Monica Lispi, Thomas D'Hooghe, Antonio La Marca

Onderzoeksoutput: Articlepeer review

6 Citaten (Scopus)
49 Downloads (Pure)

Samenvatting

A high ovarian response to conventional ovarian stimulation (OS) is characterized by an increased number of follicles and/or oocytes compared with a normal response (10-15 oocytes retrieved). According to current definitions, a high response can be diagnosed before oocyte pick-up when >18-20 follicles ≥11-12 mm are observed on the day of ovulation triggering; high response can be diagnosed after oocyte pick-up when >18-20 oocytes have been retrieved. Women with a high response are also at high risk of early ovarian hyper-stimulation syndrome (OHSS)/or late OHSS after fresh embryo transfers. Women at risk of high response can be diagnosed before stimulation based on several indices, including ovarian reserve markers (anti-Müllerian hormone [AMH] and antral follicle count [AFC], with cutoff values indicative of a high response in patients with PCOS of >3.4 ng/mL for AMH and >24 for AFC). Owing to the high proportion of high responders who are at the risk of developing OHSS (up to 30%), this educational article provides a framework for the identification and management of patients who fall into this category. The risk of high response can be greatly reduced through appropriate management, such as individualized choice of the gonadotropin starting dose, dose adjustment based on hormonal and ultrasound monitoring during OS, the choice of down-regulation protocol and ovulation trigger, and the choice between fresh or elective frozen embryo transfer. Appropriate management strategies still need to be defined for women who are predicted to have a high response and those who have an unexpected high response after starting treatment.

Originele taal-2English
Artikelnummer102301
TijdschriftBest Practice & Research Clinical Obstetrics and Gynaecology
Volume86
Vroegere onlinedatum27 dec. 2022
DOI's
StatusPublished - feb. 2023

Bibliografische nota

Funding Information:
This study was funded by Merck (CrossRef Funder ID: 10.13039/100009945 ). Merck Healthcare KGaA (Darmstadt, Germany) designed and approved the study, took part in data collection and data analysis, and contributed to the data interpretation and final draft of the manuscript.

Funding Information:
Medical writing assistance was provided by Steven Goodrick, inScience Communications, Springer Healthcare Ltd., London, UK, and funded by Merck Healthcare KGaA , Darmstadt, Germany.

Funding Information:
This study was funded by Merck (CrossRef Funder ID: 10.13039/100009945). Merck Healthcare KGaA (Darmstadt, Germany) designed and approved the study, took part in data collection and data analysis, and contributed to the data interpretation and final draft of the manuscript.Medical writing assistance was provided by Steven Goodrick, inScience Communications, Springer Healthcare Ltd. London, UK, and funded by Merck Healthcare KGaA, Darmstadt, Germany.

Publisher Copyright:
© 2023 The Authors

Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.

Vingerafdruk

Duik in de onderzoeksthema's van 'Treatment algorithms for high responders: What we can learn from randomized controlled trials, real-world data and models'. Samen vormen ze een unieke vingerafdruk.

Citeer dit